Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BAY2701250 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| i.v. infusion cohorts | EXPERIMENTAL | Each participant will receive a single dose of study intervention, either BAY2701250 or placebo. Study intervention will be administered by means of short time i.v. infusion. Up to 8 dose steps are planned to be investigated for i.v. administration. |
| s.c. injection cohorts | EXPERIMENTAL | Each participant will receive a single dose of study intervention, either BAY2701250 or placebo. Study intervention will be administered by means of s.c. injection. Up to 2 dose steps are planned to be investigated for s.c. administration. |
| Name | Type | Description |
|---|---|---|
| BAY2701250 IV | DRUG | Single does, intravenous infusion |
| Placebo IV | DRUG | Matching placebo for BAY2701250 IV |
| BAY2701250 SC | DRUG | Single dose, subcutaneous injection will be administered into abdominal subcutaneous fat tissue |
| Placebo SC | DRUG | Matching placebo for BAY2701250 SC |
Inclusion Criteria: * Male, white participants aged 18 to 45 years * Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, ECG and vital signs * Body weight ≥ 70 kg and ≤ 100 kg as well as body mass index (BMI) wi...
BAY2701250 is an investigational small molecule being developed for pulmonary hypertension due to left heart disease. It is a cardiovascular therapy currently in Phase 1 clinical development. The drug is not approved and remains under study to evaluate its safety, effects on the body, and how it moves through the body.
BAY2701250 is being developed by Bayer AG, a pharmaceutical company traded under the ticker BAYRY. The company is conducting clinical research on this investigational small molecule for the treatment of pulmonary hypertension due to left heart disease.
BAY2701250 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains under investigation for pulmonary hypertension due to left heart disease.
BAY2701250 has one completed Phase 1 clinical trial, identified as NCT06048120. This study enrolled 82 healthy male participants in Germany and evaluated the safety, tolerability, and pharmacokinetics of a single dose administered as an intravenous infusion or subcutaneous injection.
The mechanism of action for BAY2701250 has not been disclosed in available information. It is classified as a small molecule therapeutic being investigated for pulmonary hypertension due to left heart disease, but its specific molecular target is not publicly detailed.